Patient-friendly summary
If you read nothing else
Bottom line
Myofascial pain syndrome is a complex condition that may require a multimodal treatment approach; worth discussing with your provider.
Moderate evidencePublished
Evidence hierarchy
Study participants
patients with musculoskeletal pain
Words decoded
- Myofascial pain syndrome
- — A type of pain that comes from muscles and the connective tissue around them, often causing pain in other areas of the body too.
- Trigger points
- — Specific spots in the muscle that are very sensitive to touch and can cause pain in other parts of the body.
- Multimodal treatment
- — Using more than one type of treatment to address a health issue, like combining physical therapy with medication.
Full research — for clinicians and curious readers
Study Summary
Background
Myofascial pain syndrome (MPS) is one of the most common causes of acute and chronic musculoskeletal pain, affecting 20-95% of patients presenting to general medicine and pain management centers. Despite its prevalence, MPS remains poorly understood and often undertreated. The condition involves trigger points - localized painful areas in skeletal muscle containing taut bands that can cause referred pain patterns. MPS can exist independently or alongside other musculoskeletal conditions, making diagnosis and treatment challenging.
The economic and personal burden of this condition is substantial, yet there's limited consensus on optimal treatment approaches.
What They Did
The authors conducted a comprehensive narrative review examining the current understanding of myofascial pain syndrome. They analyzed existing literature on prevalence, pathophysiology, clinical presentation, diagnosis, and evidence-based treatments. The review covers regional variations of MPS (cervical, lumbar, abdominal, pelvic), explores the relationship between trigger points and other pain conditions, and evaluates multiple treatment modalities including physical therapy, pharmacotherapy, trigger point injections, botulinum toxin, and behavioral interventions. They also examined the distinction between MPS and fibromyalgia, addressing common diagnostic confusion.
What They Found
The prevalence of MPS varies widely (20-95%) depending on the population studied, with peak occurrence between ages 27-50 years. Trigger points can be active (causing spontaneous pain) or latent (asymptomatic but painful when pressed). The pathophysiology involves abnormal motor end plate function with irregular acetylcholine release, creating sustained muscle contraction and local ischemia. This leads to release of sensitizing substances that perpetuate the pain cycle.
Treatment effectiveness varies significantly, with multimodal approaches showing the best outcomes. Physical therapy and trigger point injections are commonly used, but evidence for superiority of specific techniques is limited. Botulinum toxin shows promise for refractory cases but evidence remains mixed.
What This Means
This review highlights that MPS is a major contributor to musculoskeletal pain that requires early recognition and comprehensive treatment. Clinicians should use multimodal approaches combining physical therapy, patient education, ergonomic correction, and when appropriate, injection therapy. The condition is distinct from fibromyalgia and requires different treatment strategies. More high-quality research is urgently needed to establish evidence-based treatment protocols, particularly for injection techniques and emerging therapies like botulinum toxin.
Early intervention with comprehensive care appears crucial for optimal outcomes, as patients with MPS tend to have worse outcomes than those with discrete musculoskeletal pathology.
- MPS Prevalence in Pain Clinics
- 20-95%
- Responsible for Back Pain
- 85%
- Latent Trigger Points in Healthy Adults
- 45-55%
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| MPS affects 20-95% of patients presenting to pain clinics | Wide prevalence range reflects diagnostic challenges and patient population variations | High |
| Trigger points involve abnormal motor end plate function | Irregular acetylcholine release creates sustained muscle contraction and local ischemia | High |
| Multimodal treatment approach is most effective | Combination of physical therapy, injections, and patient education shows best outcomes | High |
| MPS is distinct from fibromyalgia | Localized trigger points with referred pain patterns vs widespread tender points | Medium |
| Botulinum toxin shows promise for refractory cases | Limited evidence but may be considered when other treatments fail | Medium |
| Early intervention is crucial for optimal outcomes | Patients with MPS tend to do worse than those with discrete musculoskeletal pathology | High |
Strengths
- Comprehensive coverage of all aspects of myofascial pain syndrome
- Clear distinction between MPS and fibromyalgia
- Practical clinical guidance for diagnosis and treatment
- Evidence-based recommendations with critical analysis
Limitations
- Narrative review without systematic methodology
- Limited high-quality evidence for many treatment modalities
- Wide variation in prevalence estimates reflects diagnostic challenges
- Lack of standardized diagnostic criteria hampers research
Key Takeaways for Patients
What This Means for You
Myofascial pain syndrome is very common and affects up to 95% of people with muscle pain
The condition involves trigger points in muscles that can cause pain in other areas of your body
Treatment works best when multiple approaches are used together, including physical therapy and education
Early treatment is important - waiting can make the condition harder to treat
This condition is different from fibromyalgia and requires different treatment approaches
Read the Full Paper
Access the complete peer-reviewed study from Best Practice & Research Clinical Rheumatology